57276-33-2 Usage
General Description
1-Cyclopropyl-2-(3-pyridinyl)ethanone, also known as cyproconazole, is an organic compound frequently used as a fungicide. Its chemical structure consists of a cyclopropyl ring and a pyridinyl group, leading to its potent and specific antifungal activity. Cyproconazole is commonly used in agriculture to control a wide range of fungal diseases on various crops, such as cereals, oilseed rape, and bananas. It functions by inhibiting ergosterol biosynthesis, a key component of fungal cell membranes, ultimately disrupting their growth and reproduction. Due to its effectiveness and low toxicity towards non-target organisms, cyproconazole has become a popular choice among farmers and has been widely approved for use in many countries.
Check Digit Verification of cas no
The CAS Registry Mumber 57276-33-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,7,2,7 and 6 respectively; the second part has 2 digits, 3 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 57276-33:
(7*5)+(6*7)+(5*2)+(4*7)+(3*6)+(2*3)+(1*3)=142
142 % 10 = 2
So 57276-33-2 is a valid CAS Registry Number.
57276-33-2Relevant articles and documents
Small molecule that reverses dexamethasone resistance in t-cell acute lymphoblastic leukemia (T-ALL)
Cantley, Alexandra M.,Welsch, Matthew,Ambesi-Impiombato, Alberto,Sanchez-Martin, Marta,Kim, Mi-Yeon,Bauer, Andras,Ferrando, Adolfo,Stockwell, Brent R.
supporting information, p. 754 - 759 (2014/08/05)
Glucocorticoids are one of the most utilized and effective therapies in treating T-cell acute lymphoblastic leukemia. However, patients often develop resistance to glucocorticoids, rendering these therapies ineffective. We screened 9517 compounds, selected for their lead-like properties, chosen from among 3372615 compounds, against a dexamethasone-resistant T-ALL cell line to identify small molecules that reverse glucocorticoid resistance. We synthesized analogues of the most effective compound, termed J9, from the screen in order to define the scaffolds structure-activity relationship. Active compounds restored sensitivity to glucocorticoids through upregulation of the glucocorticoid receptor. This compound and mechanism may provide a strategy for overcoming glucocorticoid resistance in patients with T-ALL.
